Isomorphic Labs announces Series B financing
Isomorphic Labs →Isomorphic Labs announced a Series B financing of [figure hidden] led by Thrive Capital. Existing backers Alphabet and GV participated alongside new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The company described plans to develop and deploy its AI drug-design engine, expand therapeutic programs toward clinical development and recruit AI, engineering, drug-design and clinical personnel. Its announcement identified London headquarters and offices in Lausanne and Cambridge, Massachusetts. The disclosed total belongs to the financing round, not to any individual investor. The release names the operating business but does not establish the precise legal recipient or allocate proceeds among its subsidiaries.